| Except where noted otherwise, data are given for|
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references
WikiDoc Resources for
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
The benzodiazepines (pronounced [ˌbɛnzoː.daɪˈæzəˌpiːn], often abbreviated to "benzos") are a class of psychoactive drugs with varying hypnotic, sedative, anxiolytic, anticonvulsant, muscle relaxant and amnesic properties, which are mediated by slowing down the central nervous system. Benzodiazepines are useful in treating anxiety, insomnia, agitation, seizures, and muscle spasms, as well as alcohol withdrawal. They can also be used before certain medical procedures such as endoscopies or dental work where tension and anxiety are present, and prior to some unpleasant medical procedures in order to induce sedation and amnesia for the procedure. Another use is to counteract anxiety-related symptoms upon initial use of SSRIs and other antidepressants, or as an adjunctive treatment. Recreational stimulant users often use benzodiazepines as a means of "coming down" (see: Drug abuse). Benzodiazepines are also used to treat the panic that can be caused by hallucinogen intoxication.
The long-term use of benzodiazapines can cause physical dependence. The use of benzodiazepines should therefore commence only after medical consultation and benzodiazepines should be prescribed the smallest dosage possible to provide an acceptable level of symptom relief. Dependence varies with the benzodiazepine used and with the user.
The first benzodiazepine, chlordiazepoxide (Librium) was discovered serendipitously in 1954 by the Austrian scientist Leo Sternbach (1908–2005), working for the pharmaceutical company Hoffmann–La Roche. Chlordiazepoxide was synthesised from work on a chemical dye, quinazolone-3-oxides. Initially, he discontinued his work on the compound Ro-5-0690, but he "rediscovered" it in 1957 when an assistant was cleaning up the laboratory. Although initially discouraged by his employer, Sternbach conducted further research that revealed the compound was a very effective tranquilizer. Tests revealed that the compound had hypnotic, anxiolytic and muscle relaxant effects. Three years later chlordiazepoxide was marketed as a therapeutic benzodiazepine medication under the brand name Librium. Following chlordiazepoxide in 1963 diazepam hit the market under the brand name Valium, followed by many further benzodiazepine compounds which were introduced over the subsequent years and decades.
The original chemical name of chlordiazepoxide was methaminodiazepoxide but it was changed to chlordiazepoxide. It was marketed under the trade name Librium, derived from the final syllables of equilibrium. In 1959 it was used by over 2,000 physicians and more than 20,000 patients. It was described as "chemically and clinically different from any of the tranquilizers, psychic energizers or other psychotherapeutic drugs now available." During studies, chlordiazepoxide induced muscle relaxation and a quieting effect on laboratory animals like mice, rats, cats, and dogs. Fear and aggression were eliminated in much smaller doses than those necessary to produce hypnosis. Chlordiazepoxide is similar to phenobarbital in its anticonvulsant properties. However, it lacks the hypnotic effects of barbiturates. Animal tests were conducted in the Boston Zoo and the San Diego Zoo. Forty-two hospital patients admitted for acute and chronic alcoholism, and various psychoses and neuroses were treated with chlordiazepoxide. In a majority of the patients, anxiety, tension, and motor excitement were "effectively reduced." The most positive results were observed among alcoholic patients. It was reported that ulcers and dermatologic problems, both of which involve emotional factors, were reduced by chlordiazepoxide.
Chlordiazepoxide enabled the treatment of emotional disturbances without a loss of mental acuity or alertness. It assisted persons burdened by compulsive reactions like one that felt compelled to count the slats on venetian blinds upon entering a room.
Dr. Carl F. Essig of the Addiction Research Center of the National Institute of Mental Health spoke at a symposium on drug abuse at an annual meeting of the American Association for the Advancement of Science, in December 1963. He named meprobamate, glutethimide, ethinamate, ethchlorvynol, methyprylon, and chlordiazepoxide as drugs whose usefulness can hardly be questioned. However, Essig labeled these newer products as drugs of addiction, like barbiturates, whose habit-forming qualities were more widely-known. He mentioned a 90-day study of chlordiazepoxide, which concluded that the automobile accident rate among 68 users was ten times higher than normal. Participants' daily dosage ranged from 5 to 100 milligrams.
In 1963, approval for use was given to diazepam (Valium), a "simplified" version of chlordiazepoxide, primarily to counteract anxiety symptoms. Sleep-related problems were treated with nitrazepam (Mogadon), which was introduced in 1965, temazepam (Restoril), which was introduced in 1969, and flurazepam (Dalmane), which was introduced in 1973.
The core chemical structure of "classical" benzodiazepine drugs is a fusion between the benzene and diazepine ring systems. Many of these drugs contain the 5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one substructure (see figure to the above right). Benzodiazepines are molecularly similar to several groups of drugs, some of which share similar pharmacological properties, including the quinazolinones, hydantoins, succinimides, oxazolidinediones, barbiturates and glutarimides.
Most benzodiazepines are administered orally; however, administration can also occur intravenously, intramuscularly, sublingually or as a suppository. Common benzodiazepines and their primary trade names include:
- brotizolam (Lendormin)
- estazolam (ProSom)
- flunitrazepam (Rohypnol; Hypnodorm)
- flurazepam (Dalmane)
- loprazolam (Dormonoct)
- lormetazepam (Loramet)
- midazolam (Dormicum; Versed)
- nimetazepam (Ermin)
- nitrazepam (Mogadon; Alodorm)
- temazepam (Restoril; Normison)
- triazolam (Halcion)
- alprazolam (Xanax)
- bromazepam (Lexotan; Lexotanil)
- chlordiazepoxide (Librium)
- clonazepam (Rivotril; Klonopin)
- clorazepate (Tranxene)
- diazepam (Valium)
- lorazepam (Ativan; Temesta; Tavor)
- oxazepam (Serax; Serepax)
- prazepam (Centrax; Lysanxia)
A related class of drugs that also work on the benzodiazepine receptors, the nonbenzodiazepines, has recently been introduced. Nonbenzodiazepines are molecularly distinct from benzodiazepines and have less addictive potential, while still offering benefits very similar to those of benzodiazepines.
Duration of action
Benzodiazepines are commonly divided into three groups by their half-lives: Short-acting compounds have a half-life of less than 12 hours, and have few residual effects if taken before bedtime, but rebound insomnia may occur and they might cause wake-time anxiety. Intermediate-acting compounds have a half-life of 12–24 hours, may have residual effects in the first half of the day. Rebound insomnia however is more common upon discontinuation of short-acting benzodiazepines. Daytime withdrawal symptoms are also a problem with prolonged usage of short-acting benzodiazepines, including daytime anxiety. Long-acting compounds have a half-life greater than 24 hours. Strong sedative effects typically persist throughout the next day if long-acting preparations are used for insomnia. Accumulation of the compounds in the body may occur. The elimination half-life may greatly vary between individuals, especially the elderly. Shorter-acting compounds are usually best for their hypnotic effects, whereas longer-acting compounds are usually better for their anxiolytic effects. Benzodiazepines with shorter half-lives tend to be able to produce tolerance and addiction quicker, as the drug does not last in the system for as long, with resultant interdose withdrawal phenomenon and next-dose craving. Although short-acting drugs are more commonly prescribed for insomnia, there are exceptions to the rules, such as alprazolam being prescribed as an anxiolytic more than a hypnotic, despite possessing a short half-life.
Mechanism of action
Benzodiazepines produce a range of effects from depressing to stimulating the central nervous system via modulating the GABAA receptor, the most prolific inhibitory receptor within the brain. The GABAA receptor is made up from 5 subunits out of a possible 19, and GABAA receptors made up of different combinations of subunits have different properties, different locations within the brain, and different activities relative to pharmacological and clinical effects.
Benzodiazepines bind at the interface of the α and γ subunits on the GABA A receptor. Benzodiazepine binding also requires that alpha subunits contain a histidine amino acid residue, (i.e., α1, α2, α3 and α5 containing GABAA receptors). For this reason, benzodiazepines show no affinity for α4 and α6 subunits containing GABAA receptors, which contain an arginine instead of a histidine residue. Other sites on the GABAA receptor also bind neurosteroids, barbiturates and certain anesthetics.
In order for GABAA receptors to be sensitive to the action of benzodiazepines, they need to contain both an α and a γ subunit, where the benzodiazepine binds at the interface. Once bound, the benzodiazepine locks the GABAA receptor into a conformation where the neurotransmitter GABA has much higher affinity for the GABAA receptor, increasing the frequency of opening of the associated chloride ion channel and hyperpolarizing the membrane. This potentiates the inhibitory effect of the available GABA, leading to sedatory and anxiolytic effects. As mentioned above, different benzodiazepines can have different affinities for GABAA receptors made up of different collection of subunits. For instance, benzodiazepines with high activity at the α1 are associated with sedation, whereas those with higher affinity for GABAA receptors containing α2 and/or α3 subunits have good anti-anxiety activity. Benzodiazepines also bind to glial cell membranes.
Benzodiazepines are full agonists at the benzodiazepine receptor producing anxiolytic and sedating properties.
Compounds that bind to the benzodiazepine receptor and enhance the GABA receptor function are termed benzodiazepine receptor agonists and display sedative/hypnotic properties. Compounds that, in the absence of agonist, have no apparent activity but that competitively inhibit the binding of agonists to the receptor are called benzodiazepine receptor antagonists. Ligands that decrease GABA function are termed benzodiazepine receptor inverse agonists. Full inverse agonists have potent convulsant activities.
Some compounds lie somewhere between being full agonists or full antagonists, and are termed either partial agonists or partial antagonists. There has been interest in partial agonists for the benzodiazepine receptor with evidence that complete tolerance may not occur with chronic use, with partial agonists demonstrating continued anxiolytic properties with reduced sedation, dependence, and withdrawal problems.
The anticonvulsant properties of benzodiazepines may be in part or entirely due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.
Benzodiazepines have a number of therapeutic uses, are well-tolerated, and are very safe and effective drugs in the short term for a wide range of conditions.
Use as anticonvulsants
Benzodiazepines are potent anticonvulsants and have life-saving properties in the acute management of status epilepticus. The most commonly-used benzodiazepines for seizure control are lorazepam and diazepam. A meta-analysis of 11 clinical trials concluded that lorazepam was superior to diazepam in treating persistent seizures. Although diazepam is much longer-acting than lorazepam, lorazepam has a more prolonged anticonvulsant effect. This is because diazepam is very lipid-soluble and highly protein-bound, and has a very large distribution of unbound drug, resulting in diazepam's having only a 20– to 30-minute duration of action against status epilepticus. Lorazepam, however, has a much smaller volume of distribution of unbound drug, which results in a more prolonged duration of action against status epilepticus. Lorazepam can therefore be considered superior to diazepam, at least in the initial stages of treatment of status epilepticus.
Use as anxiolytics
Benzodiazepines possess anti-anxiety properties and can be useful for the short-term treatment of severe anxiety. Benzodiazepines are usually administered orally for the treatment of anxiety; however, occasionally lorazepam or diazepam may be given intravenously for the treatment of panic attacks.
A panel of over 50 peer-nominated internationally recognized experts in the pharmacotherapy of anxiety and depression judged the benzodiazepines, especially combined with an antidepressant, as the mainstays of pharmacotherapy for anxiety disorders.
Despite increasing focus on the use of antidepressants and other agents for the treatment of anxiety, benzodiazepines have remained a mainstay of anxiolytic pharmacotherapy due to their robust efficacy, rapid onset of therapeutic effect, and generally favorable side effect profile. Treatment patterns for psychotropic drugs appear to have remained stable over the past decade, with benzodiazepines being the most commonly used medication for panic disorder.
Use for insomnia
Hypnotic benzodiazepines have strong sedative effects, and certain benzodiazepines therefore are often prescribed for the management of insomnia. Longer-acting benzodiazepines, such as nitrazepam, have side-effects that may persist into the next day, whereas the more intermediate-acting benzodiazepines (for example, temazepam) may have less "hangover" effects the next day. Benzodiazepine hypnotics should be reserved for short-term courses to treat acute conditions, as tolerance and dependence may occur if these benzodiazepines are taken regularly for more than a few weeks.
Use as a premedication before procedures
Benzodiazepines can be very beneficial as premedication before surgery, especially in those that are anxious. Usually administered a couple of hours before surgery, benzodiazepines will bring about anxiety relief and also produce amnesia. Amnesia can be useful in this situation, as patients will not be able to remember any unpleasantness from surgery. Lorazepam can be utilized in patients who are particularly anxious about dental procedures. Alternatively nitrous oxide can be administered in dental phobia due to its sedative and dissociative effects, its fast onset of action, and its extremely short duration of action.
Use in intensive care
Benzodiazepines can be very useful in intensive care to sedate patients receiving mechanical ventilation, or those in extreme distress or severe pain. Caution should be exercised in this situation due to the occasional scenario of respiratory depression, and benzodiazepine overdose treatment facilities should be available.
The following are some of the criteria for Intensive care unit monitoring
• Age greater than 40 with concomitant medical illness e.g. cardiac disease with failure, ischemia or angina, recent infarction • Severe electrolyte imbalances especially with ECG changes, severe acid base disturbances • Hemodynamic instability • Respiratory insufficiency, hypoxemia and or hypercapnia • Potentially serious infections, including sepsis • GI pathology including pancreatitis, GI bleeding, fulminant hepatic failure, peritonitis • Persistent hyperthermia (Tmax > 39 0 or 1030 F) • Rhabdomyolysis • Renal failure • Prior history of severe Delirium Tremens • Need for IV benzodiazepines or other IV drips to control withdrawal
Use in alcohol dependence
Benzodiazepines have been shown to be safe and effective, particularly for preventing or treating seizures and delirium, and are the preferred agents for treating the symptoms of alcohol withdrawal syndrome. The choice of agent is based on pharmacokinetics. The most commonly used benzodiazepines in the management of alcohol withdrawal are Diazepam (Valium) and chlordiazepoxide (Librium), two long-acting agents, and lorazepam (Ativan) and oxazepam (Serax), two intermediate acting agents. The long half-life of diazepam and chlordiazepoxide make withdrawal smoother, and rebound withdrawal symptoms are less likely to occur. The two intermediate-acting agents have excellent records of efficacy. Chlordiazepoxide is the benzodiazepine of choice in uncomplicated alcohol withdrawal. Oxazepam is the most commonly used benzodiazepine in managing alcohol withdrawal symptoms. It is the benzodiazepine of choice in treating severe alcohol withdrawal symptoms, and it's often used in patients who metabolize medications less effectively, particularly the elderly and those with cirrhosis. Lorazepam is the only benzodiazepine with predictable intramuscular absorption (if intramuscular administration is necessary) and it's the most effective in preventing and controlling seizures. Phenazepam is another benzodiazepine which has been used to treat alcohol withdrawal with excellent efficacy. In Russia, it is preferred over diazepam in the management of alcohol withdrawal.
Use in muscular disorders
Benzodiazepines are well known for their strong muscle-relaxing properties, and can be useful in the treatment of muscle spasms, for example, Tetanus or spastic disorders  and Restless legs syndrome.
Use in acute mania
Mania, a mood disorder, is a state of extreme mood elevation and is a diagnosable serious psychiatric disorder. Benzodiazepines can be very useful in the short-term treatment of acute mania, until the effects of Lithium or neuroleptics take effect. Benzodiazepines bring about rapid tranquillisation and sedation of the manic individual, therefore benzodiazepines are a very important tool in the management of mania. Both clonazepam and lorazepam are used for the treatment, with some evidence that clonazepam may be superior in the treatment of acute mania.
The following list summarises the side effects which may occur from use of benzodiazepines.
- stomach upset
- Blurred vision
- Impaired coordination
- Changes in heart rate
- Hangover effect (grogginess)
- Dreaming or nightmares
- Chest pain
- Vision changes
- Paradoxical reactions
Severe behavioral changes resulting from benzodiazepines have been reported including mania, schizophrenia, anger, impulsivity, and hypomania. Individuals with borderline personality disorder appear to have a greater risk of experiencing severe behavioral or psychiatric disturbances from benzodiazepines. Aggression and violent outbursts can also occur with benzodiazepines, particularly when they are combined with alcohol. Recreational abusers and patients on high-dosage regimes may be at an even greater risk of experiencing paradoxical reactions to benzodiazepines. Paradoxical reactions may occur in any individual on commencement of therapy and initial monitoring should take into account the risk of increase in anxiety or suicidal thoughts.
When benzodiazepines are used as an adjunct in the treatment of seizures, an increase in dosage of the primary agent may be required. The concomitant administration of benzodiazepines and anti-convulsants may precipitate an increase in certain seizure activity, specifically tonic-clonic seizures.
In a letter to the British Medical Journal, it was reported that a high proportion of parents referred for actual or threatened child abuse were taking drugs at the time, often a combination of benzodiazepines and tricyclic antidepressants. Many mothers described that instead of feeling less anxious or depressed, they became more hostile and openly aggressive towards the child as well as to other family members while consuming tranquilizers. The author warned that environmental or social stresses such as difficulty coping with a crying baby combined with the effects of tranquilizers may precipitate a child abuse event.
Paradoxical rage reactions from benzodiazepines are thought to be due to partial deterioration from consciousness, generating automatic behaviors, fixation amnesia, and aggressiveness from disinhibition with a possible serotonergic mechanism playing a role.
Physical dependence and withdrawal
Long-term benzodiazepine usage, in general, leads to some form of tolerance and/or dependence with the appearance of a benzodiazepine withdrawal syndrome when the benzodiazepines are stopped or the dose is reduced. However, it is important to distinguish between addiction to and normal physical dependence on benzodiazepines. Intentional abusers of benzodiazepines usually have other substance abuse problems. Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. F.
Regular use of benzodiazepines at prescribed levels for six weeks was found to produce a significant risk of dependence, with resultant withdrawal symptoms appearing on abrupt discontinuation in a study assessing diazepam and buspirone. However, with abrupt withdrawal after six weeks of treatment with buspirone, no withdrawal symptoms developed. Various studies have shown between 20–100% of patients prescribed benzodiazepines at therapeutic dosages long term are physically dependent and will experience withdrawal symptoms.
Benzodiazepine dependence is a frequent complication when they are prescribed for or taken for longer than four weeks, with physical dependence and withdrawal symptoms being the most common problem, but also occasionally drug-seeking behavior. Withdrawal symptoms include anxiety, perceptual disturbances, distortion of all the senses, dysphoria, and, in rare cases, psychosis, and epileptic seizures. The risk factors for benzodiazepine dependence are long-term use beyond four weeks, use of high doses, and use of potent short-acting benzodiazepines among those with certain pre-existing personality characteristics such as dependent personalities, and those prone to drug abuse.
Previously, physical dependence on benzodiazepines was largely thought to occur only in people on high-therapeutic-dose ranges, and low- or normal-dose dependence was not suspected until the 1970s; and it wasn't until the early 1980s that it was confirmed. However, low-dose dependence is now a recognized clinical disadvantage of benzodiazepines, and severe withdrawal syndromes can occur from these low doses of benzodiazepines even after gradual dose reduction. Low dose dependence has now been clearly demonstrated in both animal studies and human studies.
In an animal study of four baboons on low-dose benzodiazepine treatment, three out of the four baboons demonstrated physical dependence and developed flumazenil-precipitated withdrawal symptoms after only two weeks of low-dose benzodiazepine treatment. Furthermore, the baboons on low-dose therapy did not develop more severe flumazenil-precipitated withdrawal symptoms because low-dose benzodiazepine therapy was continued over a period of 6–10 months, suggesting rapid onset of dependence with benzodiazepines and suggesting that physical dependence was complete after two weeks of chronic, low-dose benzodiazepine treatment. In another animal study, physical dependence was demonstrated with withdrawal signs appearing after only seven days of low-dose benzodiazepine treatment, and withdrawal signs appeared after only three days after high-dose treatment, which demonstrated the extremely rapid development of tolerance and dependence on benzodiazepines, at least in baboons. It was also found that previous exposure to benzodiazepines sensitized baboons to the development of physical dependence.
In humans, chronic, low-therapeutic-dose dependence was clearly demonstrated using flumazenil to show physical dependence and withdrawal signs. Withdrawal symptoms experienced by the chronic therapeutic low-dose subjects included increased ratings of dizziness, blurred vision, heart pounding, feelings of unreality, pins and needles, nausea, sweatiness, noises louder than usual, jitteriness, things moving, sensitivity to touch. In another study of 34 low-dose benzodiazepine users, physiological dependence was demonstrated by the appearance of withdrawal symptoms in 100% of those who received flumazenil whereas those receiving placebo experienced no withdrawal signs. It was also found that those dependent on low doses of benzodiazepines with a history of panic attacks were at an increased risk of suffering panic attacks due to flumazenil precipitated benzodiazepine withdrawal. It has been estimated that 30–45% of chronic low dose benzodiazepine users are dependent and it has been recommended that benzodiazepines even at low dosage be prescribed for a maximum of 7–14 days to avoid dependence.
Some controversy remains, however, in the medical literature as to the exact nature of low-dose dependence and the difficulty in getting patients to discontinue their benzodiazepines, with some papers attributing the problem to predominantly drug-seeking behavior and drug craving, whereas other papers have found the opposite, attributing the problem to a problem of physical dependence with drug-seeking and craving not being typical of low-dose benzodiazepine users.
Benzodiazepines share a similar mechanism of action with various sedative compounds that act by enhancing the GABAA receptor. Cross tolerance means that one drug will alleviate the withdrawal effects of another. It also means that tolerance of one drug will result in tolerance of another similarly-acting drug. Benzodiazepines are often used for this reason to detoxify alcohol-dependent patients, and can have life-saving properties in preventing and/or treating severe life-threatening withdrawal syndromes from alcohol, such as delirium tremens. However, although benzodiazepines can be very useful in the acute detoxification of alcoholics, benzodiazepines in themselves act as positive reinforcers in alcoholics, by increasing the desire for alcohol. Low doses of benzodiazepines were found to significantly increase the level of alcohol consumed in alcoholics. However, alcoholics dependent on benzodiazepines should not be abruptly withdrawn but be very slowly withdrawn from benzodiazepines as over-rapid withdrawal is likely to produce severe anxiety or panic, which is well known for being a relapse risk factor in alcoholics. See (benzodiazepine withdrawal syndrome).
There is also cross tolerance between alcohol, the benzodiazepines, the barbiturates, and the nonbenzodiazepine drugs, which all act by enhancing the GABAA receptor's function via modulating the chloride ion channel function of the GABAA receptor.
The Committee on the Review of Medicines
The Committee on the Review of Medicines (UK) carried out a review into benzodiazepines due to significant concerns of tolerance, drug dependence, and benzodiazepine withdrawal problems and other adverse effects. The committee found that benzodiazepines do not have any antidepressant or analgesic properties, and are therefore unsuitable treatments for conditions such as depression, tension headaches, and dysmenorrhoea. Benzodiazepines are also not beneficial in the treatment of psychosis due to a lack of efficacy. The committee also recommended against benzodiazepines being used in the treatment of anxiety or insomnia in children. The committee was in agreement with the Institute of Medicine (USA) and the conclusions of a study carried out by the White House Office of Drug Policy and the National Institute on Drug Abuse (USA) that there was little evidence that long-term use of benzodiazepine hypnotics are beneficial in the treatment of insomnia due to the development of tolerance. Benzodiazepines tended to lose their sleep-promoting properties within 3–14 days of continuous use, and, in the treatment of anxiety, the committee found that there was little convincing evidence that benzodiazepines retain efficacy in the treatment of anxiety after 4 months of continuous use due to the development of tolerance.
The committee found that regular use of benzodiazepines may cause dependence characterized by tolerance to the therapeutic effects and the development of benzodiazepine withdrawal syndrome, which includes symptoms such as anxiety, apprehension, tremor, insomnia, nausea, and vomiting upon cessation of benzodiazepine use. Withdrawal symptoms tended to develop within 24 hours after the cessation of a short-acting benzodiazepine and within 3–10 days after intermediate-acting benzodiazepines. Withdrawal effects could occur, however, after treatment lasting only 2 weeks at therapeutic-dose levels, but with a higher tendency with habitual use beyond 2 weeks and more likely at higher doses. The withdrawal symptoms may appear to be similar to the original condition before treatment. The committee reported that all benzodiazepine therapy should be withdrawn gradually, that therapy be limited to short-term use only and only in carefully-selected patients.
It was noted in the review that alcohol can potentiate the central nervous system depressant effects of benzodiazepines and should be avoided concomitantly. These effects may affect an individual's ability to drive or operate machinery, with the elderly being more prone to these adverse effects. In the neonate, high single doses or repeated low doses have been reported to produce hypotonia, poor sucking, and hypothermia, along with irregularities in the fetal heart. Benzodiazepines should also be avoided during lactation.
Taken together, withdrawal from benzodiazepines should be gradual, as abrupt withdrawal from high doses may cause confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens. Abrupt withdrawal from lower doses may cause depression, nervousness, rebound insomnia, irritability, sweating, and diarrhoea.
Benzodiazepine withdrawal symptoms occur when benzodiazepine dosage is reduced in people who are physically dependent on benzodiazepines. Abrupt or over-rapid dosage reduction can produce severe withdrawal symptoms. Withdrawal symptoms can even occur during a very gradual and slow dosage reduction but are usually not serious.
Benzodiazepine withdrawal is best managed by transferring the physically-dependent patient to an equivalent dose of diazepam because it has the longest half-life of all of the benzodiazepines and is available in low-potency, 2-mg tablets, which can be quartered for small dose reductions. The speed of benzodiazepine reduction regimes varies from person to person, but is usually 10% every 2–4 weeks. A slow withdrawal, preferably under medical supervision by a physician that is knowledgeable about the benzodiazepine withdrawal syndrome, with the patient in control of dosage reductions coupled with reassurance that withdrawal symptoms are temporary, have been found to produce the highest success rates. The withdrawal syndrome can usually be avoided or minimized by use of a long half-life benzodiazepine such as diazepam (Valium) or chlordiazepoxide (Librium) and a very gradually tapering off the drug over a period of months, or even up to a year or more, depending on the dosage and degree of dependency of the individual. A slower withdrawal rate significantly reduces the symptoms. In fact, some people feel better and more clear-headed as the dose gradually gets lower, so withdrawal from benzodiazepines is not necessarily an unpleasant event. People that report severe experiences from benzodiazepine withdrawal have almost invariably withdrawn or been withdrawn too quickly.
Benzodiazepines are used/abused recreationally and activate the dopaminergic reward pathways in the central nervous system. Misusers of benzodiazepines develop a high degree of tolerance, coupled with dosage escalation, often increasing their dosage to very high levels. Long-term use of benzodiazepines has the potential to cause both physical and psychological dependence, and are at risk of severe withdrawal symptoms. Tolerance and dependence to benzodiazepines develop rapidly with users of benzodiazepines, demonstrating benzodiazepine withdrawal syndrome after as little as 3 weeks of continuous use. Benzodiazepines, and in particular temazepam, are sometimes used intravenously, which can lead to medical complications including abscesses, cellulitis, thrombophlebitis, arterial puncture, deep vein thrombosis, hepatitis B and C, HIV or AIDS, overdose and gangrene.
Benzodiazepine use is widespread among amphetamine users, and those that have used amphetamines and benzodiazepines have greater levels of mental health problems, social deterioration, and poorer general health. Benzodiazepine injectors are almost four times more likely to inject using a shared needle than non-benzodiazepine-using injectors. It has been concluded in various studies that benzodiazepine use causes greater levels of risk and psycho-social dysfunction among drug users. Those who use stimulants and depressant drugs are more likely to report adverse reactions from stimulant use, more likely to be injecting stimulants, and more likely to have been treated for a drug problem than those using stimulants but not depressant drugs.
Once benzodiazepine dependence has been established a clinician should first establish the average daily consumption of benzodiazepines and then convert the patient to an equivalent dose of diazepam before beginning a gradual reduction program, starting initially with 2mg-size reductions. Additional drugs, such as antidepressants like buspirone, β blockers, and carbamazepine, should not be added into the withdrawal program unless there is a specific indication for their use.
A six-year study on 51 Vietnam veterans who were drug abusers of either mainly stimulants (11 people), mainly opiates (26 people), or mainly benzodiazepines (14 people), was carried out to assess psychiatric symptoms related to the specific drugs of abuse. After six years, opiate abusers had little change in psychiatric symptomatology; 5 of the stimulant users had developed psychosis, and 8 of the benzodiazepine users had developed depression. Therefore, long-term benzodiazepine abuse and dependence seems to carry a negative effect on mental health, with a significant risk of causing depression.
Neuropsychological function can be permanently affected by abuse of certain hypnotic benzodiazepines (temazepam, nitrazepam, flunitrazepam, and nimetazepam were found to be particularly toxic), with brain damage similar to alcoholic brain damage, as was shown in a 4– to 6-year follow-up study of hypnotic abusers by Borg and others of the Karolinska Institute. The CT scan abnormalities showed dilatation of the ventricular system. However, unlike alcoholics, hypnotic abusers showed no evidence of widened cortical sulci. The study concluded that, when cerebral disorder is diagnosed in hypnotic benzodiazepine abusers, it is often permanent. An earlier study by Borg et al. found evidence of cerebral disorder in those that exclusively abused hypnotic benzodiazepines, suggesting that cerebral disorder was not the result of other substances of abuse. Anxiolytic benzodiazepines, such as diazepam, clonazepam, alprazolam, bromazepam and lorazepam were not found to have the same toxic properties of most of the hypnotics.
In a survey of police detainees carried out by the Australian Government, both legal and illegal users of benzodiazepines were found to be more likely to have lived on the streets, less likely to have been in full time work, and more likely to have used heroin or methamphetamines in the past 30 days from the date of taking part in the survey. Benzodiazepine users were also more likely to be receiving illegal incomes and more likely to have been arrested or imprisoned in the previous year. Benzodiazepines were sometimes reported to be abused alone, but most often formed part of a poly drug-using problem. Female users of benzodiazepines were more likely than men to be using heroin, whereas male users of benzodiazepines were more likely to report amphetamine use. Benzodiazepine users were more likely than non-users to claim government financial benefits, and benzodiazepine users who were also poly-drug users were the most likely to be claiming government financial benefits. Problem benzodiazepine use can be associated with crime. Those who reported using benzodiazepines alone were found to be in the mid range when compared to other drug using patterns in terms of property crimes and criminal breaches. Of the detainees reporting benzodiazepine use, one in five reported injection use, mostly of illicit temazepam, but some reported injecting prescribed temazepam or more rarely, other benzodiazepines. Injection was a concern in this survey due to increased health risks. The main problems highlighted in this survey were concerns of dependence, the potential for overdose of benzodiazepines in combination with opiates and the health problems associated with injection of benzodiazepines. The most consequential, and by far most commonly-abused benzodiazepine, was temazepam. In the U.S. several jurisdictions have reported that benzodiazepine abuse by criminal detainees has surpassed that of opiates.
Benzodiazepines have also been used as a tool of murder by serial killers, murderers, and as a murder weapon by those with the condition Munchausen syndrome by proxy. Benzodiazepines have also been used to facilitate rape or robbery crimes, and benzodiazepine dependence has been linked to shoplifting due to the fugue state induced by the drug. When benzodiazepines are used for criminal purposes against a victim they are often mixed with food or drink. Flunitrazepam, temazepam, and midazolam are the most common benzodiazepines used to facilitate date rape. Alprazolam has been abused for the purpose of carrying out acts of incest and for the corruption of adolescent girls. However, alcohol remains the most common drug involved in cases of drug rape. Although benzodiazepines and ethanol are the most frequent drugs used in sexual assaults, GHB is another potential date rape drug which has received increased media focus. Some benzodiazepines are more associated with crime than others especially when abused or taken in combination with alcohol. The potent benzodiazepine flunitrazepam (Rohypnol), which has strong amnesia producing effects can cause abusers to become cold blooded and ruthless and also cause feelings of being invincible. This has led to some acts of extreme violence to others, often leaving abusers with no recollection of what they have done in their drug-induced state. It has been proposed that criminal and violent acts brought on by benzodiazepine abuse may be related to lowered serotonin levels via enhanced GABAergic effects. Flunitrazepam has been implicated as the cause of one serial killers violent rampage, triggering off extreme aggression with anterograde amnesia. A study on forensic psychiatric patients who had abused Flunitrazepam at the time of their crimes found that the patients displayed extreme violence, lacked the ability to think clearly and experienced a loss of empathy for their victims while under the influence of flunitrazepam, and it was found that the abuse of alcohol or other drugs in combination with Flunitrazepam compounded the problem. Their behaviour under the influence of Flunitrazepam was in contrast to their normal psychological state.
Patients reporting to two emergency rooms in Canada with violence-related injuries were most often found to be intoxicated with alcohol and were significantly more likely to test positive for benzodiazepines (most commonly temazepam) than other groups of individuals, whereas other drugs were found to be insignificant in relation to violent injuries.
Overdosage of benzodiazepines, particularly when combined with alcohol or opiates, may lead to coma. The antidote for all benzodiazepines is flumazenil (Anexate), a benzodiazepine antagonist, which is occasionally used empirically in patients presenting with unexplained loss of consciousness in an emergency room setting. As with all overdose situations, the care provider must be aware of the possibility that multiple substances were utilized by the patient. Supportive measures should be put in place prior to administration of any benzodiazepine antagonist in order to protect the patient from both the withdrawal effects and possible complications arising from simultaneous utilization of chemically-unrelated pharmaceutical compounds. A determination of possible deliberate overdose should be considered with appropriate scrutiny, and precautions taken to prevent any attempt by patient to commit further bodily harm.
Flumazenil should be administered only by physicians that are familiar and suitably trained in the use of flumazenil in benzodiazepine overdose. Treating benzodiazepine overdose with flumazenil may reduce the chance of the patient being admitted to intensive care; however, caution should be exercised in the administration of flumazenil. The treating physician should bear in mind the possibility of mixed overdoses, especially mixed overdoses of other drugs or substances, as cocktails of drugs are often taken in overdose situations with their own overdose risks.
Patients suspected of overdosing on benzodiazepines that are showing significant impairment of consciousness and respiratory depression and that are likely to need endotracheal intubation and be admitted to intensive care should be considered for flumazenil therapeutic treatment to avoid intubation and artificial ventilation. The decision to administer flumazenil to a suspected benzodiazepine-overdosed patient should be made after a comprehensive clinical evaluation including a complete clinical and biochemical evaluation of the respiratory status and the patient's ability to protect his or her own airway. Flumazenil, however, should be avoided in patients suspected of taking proconvulsant drugs, e.g., tricyclic antidepressants, and patients with a history of epilepsy. Flumazenil should also be avoided in patients that have a physical dependency on benzodiazepines, as flumazenil may precipitate an acute withdrawal syndrome due to rapidly displacing benzodiazepines from the benzodiazepine receptor, thus potentially triggering severe seizures. Flumazenil should be administrated gradually and carefully to avoid any potentially serious adverse reactions associated with flumazenil usage. The minimum effective dose should be given to patients to avoid the common unpleasant psychological effects of flumazenil administration, and also to avoid potentially serious side-effects. Patients may become agitated after awakening from flumazenil and may try to leave the treatment environment. In these cases clinicians should warn the patient that leaving the facility may result in re-sedation. Flumazenil should be used only where full resuscitation equipment is immediately available.
Benzodiazepine overdose can either be intentional, accidental, or iatrogenic in nature. Flumazenil can reverse all the effects of benzodiazepines due to its specific competitive benzodiazepine receptor antagonist properties. The initial treatment, as well as diagnosis of benzodiazepine overdose, can be achieved via incremental intravenous bolus injections of flumazenil in the range of 0.1 to 0.3 mg. These dose ranges are generally well tolerated and effective in the diagnosis and treatment of benzodiazepine overdose. Many benzodiazepines are longer-acting than flumazenil, and therefore there is a significant risk of relapse into coma or respiratory depression as the flumazenil wears off. Additional boluses of flumazenil or else an infusion (0.3 to 0.5 mg/h) therefore may need to be given, depending on the half-life of the benzodiazepine. Careful monitoring after flumazenil therapy has been discontinued is warranted in order to avoid relapse of the clinical condition. In neonates and small children, intravenous flumazenil of 10 to 20 μg/kg is an effective dose range for benzodiazepine overdose. Alternative routes of administration are intramuscular, oral (20 to 25 mg three times daily or as required), and rectal, which may be used as alternatives in long-term regimens. Flumazenil can precipitate seizures in patients that have taken mixed overdoses of carbamazepine or tricyclic antidepressants; flumazenil can also precipitate benzodiazepine withdrawal symptoms; however these complications of flumazenil administration can be avoided via a careful flumazenil dose titration. Flumazenil therefore is a relatively safe and very effective treatment of benzodiazepine overdose, provided it is carried out by an experienced and knowledgeable physician in a suitable clinical environment.
From a research perspective, there are some data suggesting that temazepam may be more frequently involved in drug-related deaths than are some other benzodiazepines. Temazepam produced more sedation than did other benzodiazepines, in overdose situations. Thus, there is some reason to think that temazepam (once taken in overdose) may have greater toxicity than other benzodiazepines. 
In the united states the FDA has categorised benzodiazepines into either category D or category X benzodiazepines. International statistics show that 3.5% of women consume psychotropic drugs during pregnancy and of that 3.5% up to 85% report using benzodiazepines during pregnancy making benzodiazepines the most commonly prescribed psychotropic drug consumed during pregnancy. Approximately 0.4% of all pregnancies are to women who have used benzodiazepines chronically throughout their pregnancy. Neurodevelopmental and clinical symptoms are commonly found in babies exposed to benzodiazepines in utero. Benzodiazepine exposed babies have a low birth weight but catch up to normal babies at an early age but smaller head circumferences found in benzo babies persists. Other adverse effects of benzodiazepines taken during pregnancy are deviating neurodevelopmental and clinical symptoms including craniofacial anomalies, delayed development of pincer grasp, deviations in muscle tone and pattern of movements. Motor impairments in the babies are impeded for up to 1 year after birth. Gross motor development impairments takes 18 months to return to normal but fine motor function impairments persist. In addition to the smaller head circumference found in benzodiazepine exposed babies mental retardation and lower intelligence occurs.
All benzodiazepines are Schedule IV in the USA under the Federal Controlled Substances Act, even when not on the market (for example, nitrazepam and bromazepam). In Canada benzodiazepines are also Schedule IV.
Elsewhere in the world, however, benzodiazepines which are often subject to heavy abuse and addiction are often more strictly regulated or controlled. Temazepam, nimetazepam, and flunitrazepam are the worlds most heavily regulated benzodiazepines.
Flunitrazepam (Rohypnol), Nimetazepam (Ermin), and Temazepam (Restoril; Normison) are treated more severely under International law than other benzodiazepines. For example, in the United States, despite being Schedule IV like any other benzodiazepine, flunitrazepam is not commercially available. It also carries tougher Federal penalties for trafficking and possession than other Schedule IV drugs. With the exception of cases involving 5 grams or more of cocaine or morphine, flunitrazepam is the only controlled substance whose first-offense simple possession is a federal felony. Temazepam is the only benzodiazepine which may require specially-coded prescriptions in some states.
Throughout Europe, including the United Kingdom, temazepam and flunitrazepam also carry tougher penalties for trafficking and possession. In Ireland, temazepam and flunitrazepam are both Schedule 3 drugs under the Misuse of Drugs (Amendment) Regulations, (1993), while all other benzodiazepines are Schedule 4. As a result of continued abuse, illegal diversion, distrubtion, and clandestine manufacture in Eastern Europe, Germany is currently in the process of possibly taking temazepam off of Anlage 3 (equivalent to Schedule 3 or Class C) of the BtMG (or Betäubungsmittelgesetz, which means Narcotics Act) and placing it under Anlage 2 (equivalent to Schedule 2 or Class B). In the Netherlands, benzodiazepines are all equally classed under List 2 of the Opium Act.
In Australia, both temazepam and flunitrazepam, in all forms are restricted as Schedule 8 controlled drugs. As Schedule 8 controlled substances, it is illegal to possess either drug without an authority prescription from a registered doctor. In New Zealand, temazepam and flunitrazepam are completely illegal to possess and/or traffic. All other benzodiazepines are not illegal to possess for personal use, but distribution/traffic of any benzodiazepine is punishable by law.
In East Asia and Southeast Asia, temazepam and nimetazepam are often heavily controlled and restricted. In certain countries, triazolam, flunitrazepam, flutoprazepam, and midazolam are also restricted or controlled to certain degrees. In Hong Kong for example, temazepam and nimetazepam are regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. Triazolam, flunitrazepam, flutoprazepam, and midazolam are regulated under Schedule 2 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. Other benzodiazepines are not scheduled or controlled substances.
In Singapore, the Misuse of Drugs Act lists both temazepam and nimetazepam as Class A/Schedule I controlled drugs. Flutoprazepam, flunitrazepam, and triazolam are listed as Class C/Schedule II controlled drugs. Furthermore, a number of other benzodiazepines are regulated. Regulation of certain benzodiazepines under Schedule III was based on the relative ease by which they may be used to manufacture controlled benzodiazepines. They are as follows: camazepam, clonazepam, diazepam, estazolam, lorazepam, lormetazepam, nitrazepam, oxazepam, and prazepam. These benzodiazepines are regulated under Schedule III as controlled equipment, materials or substances useful for manufacturing controlled drugs. Restriction of these benzodiazepines is a measure against any clandestine manufacture of anyone of the controlled benzodiazepines, as seen with the growing illicit manufacture and distribution of temazepam in other regions of the world. Other benzodiazepines are not controlled drugs, but are available only by prescription and if used to manufacture any of the controlled benzodiazepines, automatically become Schedule III substances or material.
Internationally, temazepam, nimetazepam, and flunitrazepam are Schedule IV drugs under the Convention on Psychotropic Substances. Though they are classed as a Schedule IV internationally, penalties for their possession and/or trafficking are more severe than other Schedule IV drugs, including all other benzodiazepines. Temazepam and nimetazepam continue to be the most widely abused benzodiazepines worldwide.  Seizures of the two drugs by authorities are far higher in number than seizures of all the other benzodiazepines combined, including flunitrazepam. Worldwide, seizures of temazepam and nimetazepam may be comparable in number to seizures of the hypnotic, methaqualone. 
Various other countries limit the availability of benzodiazepines legally. Even though it is a commonly-prescribed class of drugs, the Medicare Prescription Drug, Improvement, and Modernization Act specifically states that insurance companies that provide Medicare Part D plans are not allowed to cover benzodiazepines.
- McKernan RM; Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ. (Jun 2000). "Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.". Nature neuroscience. 3 (6): 587-92. doi:10.1038/75761. PMID 10816315. Retrieved on 2007-07-05.
- Bulach R, Myles PS, Russnak M (2004). "Double-blind randomized controlled trial to determine extent of amnesia with midazolam given immediately before general anaesthesia.". Br J Anaesth 94 (3): 300-305. doi:10.1093/bja/aei040. PMID 15567810.
- Leikin JB, Krantz AJ, Zell-Kanter M, Barkin RL, Hryhorczuk DO (1989). "Clinical features and management of intoxication due to hallucinogenic drugs". Med Toxicol Adverse Drug Exp 4 (5): 324-50. PMID 2682130.
- Cooper, Jack R; Floyd E. Bloom, Robert H. Roth (15). The Complete Story of the Benzodiazepines, seventh (in Eng), USA: Oxford University Press. ISBN 0195103998. Retrieved on 07.
- Help For Mental Ills (Reports on Tests of Synthetic Drug Say The Results are Positive), New York Times, February 28, 1960, Page E9.
- Makers Worried On Tranquilizers, New York Times, August 28, 1960, Page F1.
- Warning Is Issued On Tranquilizers, New York Times, December 30, 1963, Page 23.
- Sternbach LH (1972). "The discovery of librium". Agents Actions 2 (4): 193-6. PMID 4557348.
- Danneberg P; Weber KH (1983). "Chemical structure and biological activity of the diazepines". Br J Clin Pharmacol 16 (Suppl 2): 231S-244S. PMID 6140944.
- Earley JV; Fryer RI, Ning RY. (Jul 1979). "Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development.". J Pharm Sci. 68 (7): 845-50. PMID 458601.
- Lemmer B (2007). "The sleep-wake cycle and sleeping pills". Physiol. Behav. 90 (2-3): 285-93. doi:10.1016/j.physbeh.2006.09.006. PMID 17049955.
- "Benzodiazepines: a summary of pharmacokinetic properties.". British journal of clinical pharmacology.. PMID 6133528.
- (Dec 1990) "Benzodiazepine use in a small community hospital. Appropriate prescribing or not?". South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. PMID 2251629.
- Pym LJ, Cook SM, Rosahl T, McKernan RM, Atack JR (2005). "Selective labelling of diazepam-insensitive GABAA receptors in vivo using [3H]Ro 15-4513". Br. J. Pharmacol. 146 (6): 817-25. doi:10.1038/sj.bjp.0706392. PMID 16184188.
- Hevers W, Lüddens H (1998). "The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes". Mol. Neurobiol. 18 (1): 35-86. PMID 9824848.
- Tardy M; Costa MF, Rolland B, Fages C, Gonnard P (Apr 1981). "Benzodiazepine receptors on primary cultures of mouse astrocytes". J Neurochem 36 (4): 1587-9. PMID 6267195.
- Atack JR (2003). "Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site". Current drug targets. CNS and neurological disorders 2 (4): 213-32. PMID 12871032.
- McLean MJ; Macdonald RL. (Feb 1988). "Benzodiazepines, but not beta carbolines, limit high-frequency repetitive firing of action potentials of spinal cord neurons in cell culture.". J Pharmacol Exp Ther. 244 (2): 789-95. PMID 2450203.
- Prasad K; Krishnan PR, Al-Roomi K, Sequeira R. (Jun 2007). "Anticonvulsant therapy for status epilepticus.". British journal of clinical pharmacology. 63 (6): 640-7. doi:10.1002/14651858.CD003723.pub2. PMID 17439538.
- Treiman DM. (1989). "Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus.". Epilepsia. 30 (2): 4-10. PMID 2670537.
- Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999). "International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997". Depress Anxiety 9 (3): 107–16. PMID 10356648.
- Uhlenhuth EH, Balter MB, Ban TA, Yang K (1995). "International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders". J Affect Disord 35 (4): 153–62. PMID 8749980.
- Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999). "Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997". Eur Neuropsychopharmacol 9 Suppl 6: S393–8. PMID 10622685.
- Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999). "International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders". J Clin Psychopharmacol 19 (6 Suppl 2): 23S–29S. PMID 10587281.
- Stevens JC, Pollack MH (2005). "Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents". J Clin Psychiatry 66 Suppl 2: 21–7. PMID 15762816.
- Bruce SE, Vasile RG, Goisman RM, et al (2003). "Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?". Am J Psychiatry 160 (8): 1432–8. PMID 12900305.
- Wilson A, Vulcano B. A double-blind, placebo-controlled trial of magnesium sulfate in the ethanol withdrawal syndrome. Alcohol Clin Exp Resp 1984;8:542-5.
- Raistrick, D, Heather N & Godfrey C (2006) "Review of the Effectiveness of Treatment for Alcohol Problems" National Treatment Agency for Substance Misuse, London http://www.nta.nhs.uk/publications/documents/nta_review_of_the_effectiveness_of_treatment_for_alcohol_problems_fullreport_2006_alcohol2.pdf
- Bottaï T; Hüe B, Hillaire-Buys D, Barbe A, Alric R, Pouget R, Petit P. (Dec 1995). "Clonazepam in acute mania: time-blind evaluation of clinical response and concentrations in plasma.". Journal of affective disorders. 36 (1-2): 21-7. PMID 8988261.
- Curtin F; Schulz P. (Mar 2004). "Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis.". Journal of affective disorders. 78 (3): 201-8. PMID 15013244.
- medicinenet. BENZODIAZEPINES - ORAL. medicinenet.com. Retrieved on 10 Apr 2008.
- Paradoxical Reactions to Benzodiazepines
- Cole JO; Kando JC. (1993). "Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines.". The Journal of clinical psychiatry. 54 (49-61): 62-3. PMID 8262890.
- Benzodiazepines — Effects on Human Performance and Behavior. Forensic Science Review (2002).
- Paradoxical Reactions to Benzodiazepines
- (1) "Letter: Tranquilizers causing aggression.". British medical journal. 1 (5952): 266. PMID 234269.
- Senninger JL; Laxenaire M. (1995). "[Violent paradoxal reactions secondary to the use of benzodiazepines]". Annales médico-psychologiques. 153 (4): 278-81. doi:10.1093/bja/aei040. PMID 7618826.
- O'brien CP (2005). "Benzodiazepine use, abuse, and dependence". J Clin Psychiatry 66 Suppl 2: 28–33. PMID 15762817.
- Murphy SM, Owen R, Tyrer P. (1989). "Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone.". The British Journal of Psychiatry : the journal of mental science. 154: 529-34. PMID 2686797.
- Ashton, CH (1997 publisher= Cambridge University Press). "Benzodiazepine Dependency", in A Baum, S. Newman, J. Weinman, R. West, C. McManus: Cambridge Handbook of Psychology & Medicine, 376-80.
- Marriott S, Tyrer P. (Aug 1993). "Benzodiazepine dependence. Avoidance and withdrawal.". Drug safety : an international journal of medical toxicology and drug experience. 9 (2): 93-103. PMID 8104417.
- Lader M. (1991). "History of benzodiazepine dependence.". Journal of substance abuse treatment. 8 (1-2): 53-9. PMID 1675692.
- Lader M. (Dec 1987). "Long-term anxiolytic therapy: the issue of drug withdrawal.". The Journal of clinical psychiatry. 48: 12-6. PMID 2891684.
- Miura S; Murasaki M (Mar 1992). "The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives).". Progress in neuro-psychopharmacology & biological psychiatry. 16 (6): 833-45. PMID 1355301.
- Lucki I; Kucharik RF. (1990). "Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam.". Psychopharmacology. 102 (3): 350-6. PMID 1979180.
- Rickels K; Case WG, Schweizer EE, Swenson C, Fridman RB. (1986). "Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients.". Psychopharmacology bulletin. 22 (2): 407-15. PMID 2877472.
- Kaminski BJ; Sannerud CA, Weerts EM, Lamb RJ, Griffiths RR. (Jul 2003). "Physical dependence in baboons chronically treated with low and high doses of diazepam.". Behavioural pharmacology. 14 (4): 331-42. PMID 12838039.
- Lukas SE; Griffiths RR. (20). "Precipitated diazepam withdrawal in baboons: effects of dose and duration of diazepam exposure.". European journal of pharmacology. 100 (2): 163-71. PMID 6428921.
- Mintzer MZ; Stoller KB, Griffiths RR. (Nov 1999). "A controlled study of flumazenil-precipitated withdrawal in chronic, low-dose benzodiazepine users." 147 (2): 200-9. PMID 10591888.
- Bernik MA; Gorenstein C, Vieira Filho AH. (1998). "Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users.". Journal of psychopharmacology (Oxford, England). 12 (2): 146-50. PMID 9694026.
- Meier PJ; Ziegler WH, Neftel K. (19). "[Benzodiazepine--practice and problems of its use]". Schweizerische medizinische Wochenschrift. 118 (11): 381-92. PMID 3287602.
- Linden M; Bär T, Geiselmann B. (May 1998). "Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions.". Psychological medicine. 28 (3): 721-9. PMID 9626728.
- Tyrer P. (1993). "Benzodiazepine dependence: a shadowy diagnosis.". Biochemical Society symposium. 59: 107-19. PMID 7910738.
- Poulos CX; Zack M. (2004). "Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers.". Behavioural pharmacology. 15 (7): 503-12. PMID 15472572.
- Khanna JM, Kalant H, Weiner J, Shah G (1992). "Rapid tolerance and cross-tolerance as predictors of chronic tolerance and cross-tolerance". Pharmacol. Biochem. Behav. 41 (2): 355-60. PMID 1574525.
- World Health Organisation - Assessment of Zopiclone
- Allan AM, Baier LD, Zhang X (1992). "Effects of lorazepam tolerance and withdrawal on GABAA receptor-operated chloride channels". J. Pharmacol. Exp. Ther. 261 (2): 395-402. PMID 1374467.
- Rooke KC. (1976). "The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice.". J Int Med Res. 4 (5): 355-9. PMID 18375.
- Committee on the Review of Medicines (29). "Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines." (pdf). Br Med J. 280 (6218): 910-2. PMID 7388368.
- Dr JG McConnell (May 2007). The Clinicopharmacotherapeutics of Benzodiazepine and Z drug dose Tapering Using Diazepam.
- Professor Heather Ashton (2002). Benzodiazepines: How They Work and How To Withdraw.
- Söderpalm B; Svensson L, Hulthe P, Johannessen K, Engel JA. (1991). "Evidence for a role for dopamine in the diazepam locomotor stimulating effect.". Psychopharmacology. 104 (1): 97-102. PMID 1679244.
- Darke S; Ross J, Cohen J. (1994). "The use of benzodiazepines among regular amphetamine users.". Addiction (Abingdon, England). 89 (12): 1683-90. PMID 7866252.
- Williamson S; Gossop M, Powis B, Griffiths P, Fountain J, Strang J. (14). "Adverse effects of stimulant drugs in a community sample of drug users.". Drug and alcohol dependence. 44 (2-3): 87-94. PMID 9088780.
- Gerada C; Ashworth M (1997). "ABC of mental health. Addiction and dependence--I: Illicit drugs". BMJ 315 (7103): 297-300. PMID 9274553.
- Woody GE; Mc Lellan AT O'Brien CP. (1979). "Development of psychiatric illness in drug abusers. Possible role of drug preference.". The New England journal of medicine. 301 (24): 1310-4. PMID 41182.
- Gossop M; Stewart D, Treacy S, Marsden J. (2002). "A prospective study of mortality among drug misusers during a 4-year period after seeking treatment.". Addiction (Abingdon, England). 97 (1): 39-47. doi:10.1046/j.1360-0443.2002.00079.x. PMID 11895269.
- Borg S; Bergman H, Engelbrektson K, Vikander B. (1989). "Dependence on sedative-hypnotics: neuropsychological impairment, field dependence and clinical course in a 5-year follow-up study.". British journal of addiction. 84 (5): 547-53. PMID 2743035.
- Borg S; Bergman H, Holm L. (Feb 1980). "Neuropsychological impairment and exclusive abuse of sedatives or hypnotics.". The American journal of psychiatry. 137 (2): 215-7. PMID 7352578.
- Benzodiazepine use and harms among police detainees in Australia. Australian Institute of Criminology (May 2007).
- Yacoubian GS. (Jan 2003). "Correlates of benzodiazepine use among a sample of arrestees surveyed through the Arrestee Drug Abuse Monitoring (ADAM) Program." 38 (1): 127-39. Substance use & misuse.. PMID 12602810.
- Missliwetz J (Jul-Aug 1981). "[Serial homicide in the Vienna-Lainz hospital]" 194 (1-2): 1-7. Archiv für Kriminologie.. PMID 7979864.
- Valentine JL; Schexnayder S, Jones JG, Sturner WQ. (Sep 1997). "Clinical and toxicological findings in two young siblings and autopsy findings in one sibling with multiple hospital admissions resulting in death. Evidence suggesting Munchausen syndrome by proxy." 18 (3): 276-81. The American journal of forensic medicine and pathology : official publication of the National Association of Medical Examiners.. PMID 9290875.
- Saito T; Takeichi S, Nakajima Y, Yukawa N, Osawa M. (Nov-Dec 1997). "A case of homicidal poisoning involving several drugs." 194 (1-2): 1-7. Journal of analytical toxicology.. PMID 9399131.
- Boussairi A; Dupeyron JP, Hernandez B, Delaitre D, Beugnet L, Espinoza P, Diamant-Berger O. (1996). "Urine benzodiazepines screening of involuntarily drugged and robbed or raped patients." 34 (6): 721-4. Journal of toxicology. Clinical toxicology.. PMID 8941203.
- Tang CP; Pang AH, Ungvari GS. (Jul 1996). "Shoplifting and robbery in a fugue state." 36 (3): 265-8. Medicine, science, and the law.. PMID 8918097.
- Ohshima T. (Jan 2006). "A case of drug-facilitated sexual assault by the use of flunitrazepam." 13 (1): 44-5. Journal of clinical forensic medicine.. PMID 16087387.
- Negrusz A; Gaensslen RE. (Aug 2003). "Analytical developments in toxicological investigation of drug-facilitated sexual assault.". Analytical and bioanalytical chemistry. 376 (8): 1192-7. doi:10.1007/s00216-003-1896-z. PMID 12682705.
- Kintz P; Villain M, Chèze M, Pépin G. (29). "Identification of alprazolam in hair in two cases of drug-facilitated incidents." 153 (2-3): 222-6. Forensic science international.. PMID 16139113.
- Weir E. (10). "Drug-facilitated date rape." 165 (1): 80. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.. PMID 11468961.
- Saint-Martin P; Furet Y, O'Byrne P, Bouyssy M, Paintaud G, Autret-Leca E. (Mar-Apr 2006). "[Chemical submission: a literature review]" 61 (2): 145-50. Thérapie.. doi:10.1093/bja/aei040. PMID 16886708.
- Dåderman A; Lidberg L. (3). "[Rohypnol should be classified as a narcotic]" 96 (9): 1005-7. Läkartidningen.. doi:10.1093/bja/aei040. PMID 10093441.
- Dåderman AM; Strindlund H, Wiklund N, Fredriksen SO, Lidberg L. (14). "The importance of a urine sample in persons intoxicated with flunitrazepam--legal issues in a forensic psychiatric case study of a serial murderer." 137 (1): 21-7. Forensic science international.. PMID 14550609.
- Dåderman AM; Fredriksson B, Kristiansson M, Nilsson LH, Lidberg L. (2002). "Violent behavior, impulsive decision-making, and anterograde amnesia while intoxicated with flunitrazepam and alcohol or other drugs: a case study in forensic psychiatric patients." 30 (2): 238-51. The journal of the American Academy of Psychiatry and the Law.. PMID 12108561.
- Macdonald S; Wells S, Giesbrecht N, Cherpitel CJ. (1). "Demographic and substance use factors related to violent and accidental injuries: results from an emergency room study." 55 (1-2): 53-61. Drug and alcohol dependence.. PMID 10402149.
- Transient changes in behaviour lead to heroin overdose: results from a case-crossover study of non-fatal overdose. Addiction (Abingdon, England). (2005).
- A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug safety : an international journal of medical toxicology and drug experience. (1997).
- BMJ (Clinical research ed.). (1995).
- National Institute for Clinical Excellence (July 2004). Self-harm The short-term physical and psychological management and secondary prevention of self-harm in primary and secondary care (PDF) 23-24. N.I.C.E. Retrieved on 20, 2007. Retrieved on Jul 2007.
- Weinbroum AA; Flaishon R, Sorkine P, Szold O, Rudick V. (Sep 1997). "A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.". Drug safety : an international journal of medical toxicology and drug experience. 17 (3): 181-96. PMID 9306053.
- Restoril (Temazepam) And Suicide
- BJC Behavioral Health. Benzodiazepines. BJC. Retrieved on 18 Apr 2008.
- F, Marchetti; Romero M, Bonati M, Tognoni G (Dec 1993). "Use of psychotropic drugs during pregnancy" (pdf). European Journal of Clinical Pharmacology 45 (6): 495-501. Springer Berlin / Heidelberg. doi:10.1007/BF00315304. ISSN 1432-1041. PMID 7908878.
- L, Laegreid; Hagberg G, Lundberg A (Apr 1992). "Neurodevelopment in late infancy after prenatal exposure to benzodiazepines--a prospective study". Neuropediatrics 23 (2): 60-7. PMID 1351263.
- L, Laegreid (1990). "Clinical observations in children after prenatal benzodiazepine exposure". Dev Pharmacol Ther 15 (3-4): 186-8. PMID 1983095.
- DEA, USA. Benzodiazepines. Drug Enforcement Agency.
- UK, Gov (Jan 2006). List of Drugs Currently Controlled Under The Misuse of Drugs Legislation. Misuse of Drugs Act UK. Retrieved on 10, 2007. Retrieved on 06 2007.
- http://www.cnb.gov.sg/ [Central Narcotics Bureau, Singapore]
- Green List -- List of psychotropic substances under international control (PDF). International Narcotics Control Board (23rd edition, August 2003). Retrieved on 2007-11-25.
- International Narcotics Control Board (INCB), 2006. Report of the International Narcotics Control Board for 2005. United Nations INCB, New York.
- Beare, M. “Structures, Strategies, and Tactics of Transnational Criminal Organizations: Critical Issues for Enforcement” Paper presented at the Australian Institute of Criminology, Australian Customs Service, and Australian Federal Police Transnational Crime Conference, Canberra
- Drugs and Crime Prevention Committee (DCPC), 2006. Inquiry into possible international epidemic of misuse/abuse of temazepam; Parliament of Victoria, Melbourne.
Benzodiazepines (N05BA, N05CD)
Bromazepam • Camazepam • Chlordiazepoxide • Cinolazepam • Clonazepam • Clorazepate • Cyprazepam • Delorazepam • Diazepam • Doxefazepam • Elfazepam • Ethyl loflazepate • Fletazepam • Fludiazepam • Fosazepam • Flunitrazepam • Flurazepam • Flutoprazepam • Gidazepam • Halazepam • Iclazepam • Lorazepam • Lormetazepam • Meclonazepam • Medazepam • Menitrazepam • Metaclazepam • Nimetazepam • Nitrazepam • Nordazepam • Oxazepam • Phenazepam • Pinazepam • Pivoxazepam • Prazepam • Quazepam • QH-II-66 • Reclazepam • Sulazepam • Temazepam • Tetrazepam • Uldazepam
|Thienobenzodiazepines||Brotizolam • Clotiazepam • Etizolam|
|1,5-Benzodiazepines||Arfendazam • Clobazam • Lofendazam • Triflubazam|
|2,3-Benzodiazepines||Girisopam • GYKI-52895 • Nerisopam • Tofisopam|
|Benzodiazepine Prodrugs||Avizafone • Rilmazafone|
|Others||Bentazepam • Ketazolam • Olanzepine • Tifluadom • Zolazepam|
cs:Benzodiazepin da:Benzodiazepin de:Benzodiazepine el:Βενζοδιαζεπίνηgl:Benzodiazepina it:Benzodiazepine he:בנזודיאזפינים nl:Benzodiazepineno:Benzodiazepin nn:Benzodiazepinsl:Benzodiazepin sr:Бензодијазепини fi:Bentsodiatsepiini sv:Bensodiazepiner
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies